Study to improve outcomes in autoimmune liver disease
Part of Digestive system, Immune system & allergy clinical trials.
This trial tests approaches to improve health outcomes for people with autoimmune liver diseases. It includes specific autoimmune conditions affecting the liver and bile ducts, and it may help your care team learn what works best for these illnesses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been clinically diagnosed with autoimmune hepatitis (AIH)
- You have been clinically diagnosed with primary sclerosing cholangitis (PSC)
- You have been clinically diagnosed with autoimmune sclerosing cholangitis (ASC)
- You have not had a liver transplant before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people diagnosed with primary biliary cholangitis or autoimmune hepatitis. It aims to learn more about these autoimmune liver conditions and may help guide better care in the future.
This study is looking at specific immune cells (T cells) in the blood of people with autoimmune hepatitis (AIH) to better understand the disease. If you have untreated AIH and meet certain criteria, you may be able to participate.
This study creates a national database for people diagnosed with primary sclerosing cholangitis (PSC). It may help researchers learn more about the condition by collecting health information from participants.
This study follows people with autoimmune hepatitis (a condition where the immune system attacks the liver) and requires key blood test results at diagnosis. It may help doctors better understand this disease and how it progresses in patients in China.
This study collects and stores samples from people with PSC (primary sclerosing cholangitis), PBC (primary biliary cholangitis), and some related liver conditions. Researchers use these samples to better understand these diseases and support future research.
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
Hear when a new Autoimmune Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.